ALBITAR MAHER has a total of 19 patent applications. Its first patent ever was published in 2006. It filed its patents most often in United States and WIPO (World Intellectual Property Organization). Its main competitors in its focus markets biotechnology, measurement and machines are MTM LAB AG, PRECISION THERAPEUTICS INC and CARIS LIFE SCIENCES LUXEMBOURG HOLDINGS.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 16 | |
#2 | WIPO (World Intellectual Property Organization) | 3 |
# | Industry | |
---|---|---|
#1 | Biotechnology | |
#2 | Measurement | |
#3 | Machines | |
#4 | Pharmaceuticals | |
#5 | Foods and drinks |
# | Technology | |
---|---|---|
#1 | Measuring microorganism processes | |
#2 | Analysing materials | |
#3 | Unspecified technologies | |
#4 | Therapeutic chemical compounds | |
#5 | Peptides | |
#6 | Unspecified technologies | |
#7 | Microorganisms | |
#8 | Enzymes | |
#9 | Medical preparations |
# | Name | Total Patents |
---|---|---|
#1 | Albitar Maher | 19 |
#2 | Keating Michael J | 5 |
#3 | Ma Wanlong | 4 |
#4 | Manshouri Taghi | 3 |
#5 | Kantarjian Hagop M | 2 |
#6 | Ma Wanglong | 2 |
#7 | Estey Elihu H | 2 |
#8 | Giles Francis J | 2 |
#9 | Giles Francis | 1 |
#10 | Zhang Xi | 1 |
Publication | Filing date | Title |
---|---|---|
US2013288236A1 | Wt1 mutations for prognosis of myeloproliferative disorders | |
US2012003653A1 | Compositions and methods for detecting mutations in JAK2 nucleic acid | |
US2010113470A1 | BCR-ABL variants | |
US2010099084A1 | Detection of npm1 nucleic acid in acellular body fluids | |
US2009142755A1 | Assay for detecting genetic abnormalities in genomic nucleic acids | |
US2009123920A1 | Jak2 mutations | |
US2008118940A1 | Proteasomal peptidase activity and the use thereof in clinical applications | |
US2007248961A1 | Methods for detecting mutations in JAK2 nucleic acid |